Lymphopenia

Lymphopenia Clinical Trial

Lymphopenia, also known as lymphocytopenia, is a condition marked by abnormally low levels of lymphocytes – white blood cells that are essential for immune defense. It can occur as a result of cancer itself or as a side effect of cancer treatments such as chemotherapy or radiation.

When lymphocyte counts fall too low, the immune system becomes less able to detect and fight infections and abnormal cells, including cancer. This compromised state can leave patients vulnerable to complications and limit their ability to continue cancer therapy.

Lymphopenia Clinical Trials

ImmunityBio’s BioShield™ platform, featuring the novel agent ANKTIVA® (N-803/NAI), has been granted Expanded Access authorization by the U.S. Food and Drug Administration (FDA) for use in patients with refractory or relapsed solid tumors and lymphopenia.
ANKTIVA® is designed to activate and expand memory T cells and natural killer (NK) cells, enhancing the immune system’s response while avoiding depletion of immune cells. By helping restore lymphocyte levels, this therapy may offer a new pathway to immune recovery for patients whose immune systems have been weakened by cancer or its treatment.

ResQ117EX-ALC – Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

This is a protocol for expanded access use of nogapendekin-alfa inbakicept (N-803/NAI) in participants with lymphopenia induced by chemotherapy, immunotherapy, and/or radiation therapy who may benefit from its use, and who are ineligible to participate in a clinical trial using NAI. The primary objective of this protocol is to evaluate the reversal and maintenance of absolute lymphocyte count (ALC) with N-803/NAI.

Select Eligibility Criteria:

• Adult patients with solid tumors who progressed on standard-of-care treatment chemotherapy and/or immunotherapy and/or radiation therapy requiring second line or greater standard-of-care treatment with:
• Chemotherapy and/or
• Radiation therapy and/or
• Immune checkpoint inhibitor therapy and/or any therapy investigator deems appropriate at that institution
• You can review a list of all eligibility criteria at ClinicalTrials.gov (link below).